Liquid Biopsy for Precision Medicine: What’s Actionable Now and What’s Next

About this episode

This episode explores the advancements in liquid biopsy for cancer detection and treatment, featuring insights from leading experts in the field.

Advances in molecular diagnostics are reshaping how cancer is detected, monitored, and treated, and liquid biopsy is becoming central to that progress. This simple blood draw can reveal key tumor biology at diagnosis and over time, providing timely insight and guiding more precise decisions throughout a patient’s journey. Clinicians now face an important challenge: knowing what is actionable today and what is coming next so more patients can benefit from the promise of these advances. As we kick off Season 7, host and patient advocate Karan Cushman expands this season’s focus on Bringing Precision Medicine to Everyone with a deeper look inside the science of liquid biopsy. The conversation features two leaders shaping the field: Dr. Christian Rolfo, Division Director of Medical Oncology at The James Comprehensive Cancer Center at Ohio State University, and Dr. Roberto Borea, Medical Oncologist and emerging investigator from the Rolfo Lab. Together, they break down the scientific momentum driving liquid biopsy forward, including tumor fraction, MRD-guided treatment strategies, resistance monitoring, fragmentomics, and the expanding frontier of early detection. They also discuss…

People in this episode

Host: Karan Cushman

Guests: Dr. Christian Rolfo, Dr. Roberto Borea

Topics covered

• liquid biopsy
• molecular diagnostics
• cancer detection
• tumor biology
• precision medicine
• treatment strategies

Keywords

• liquid biopsy
• cancer monitoring
• tumor fraction
• MRD-guided treatment
• early detection
• biomarkers

Mentioned in this episode

Organizations: The James Comprehensive Cancer Center at Ohio State University, Rolfo Lab